Literature DB >> 19322702

Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges.

Gino Marioni1, Emiliano D'Alessandro, Andy Bertolin, Alberto Staffieri.   

Abstract

CONCLUSIONS: Survivin expression should be studied as a potential hallmark of higher risk oral, oropharyngeal and laryngeal squamous cell carcinomas (SCCs) to develop loco-regional recurrences. These outcomes could have a significant impact on both the treatment modalities and the intensity of post-treatment follow-up. Further investigation is necessary before considering elective neck dissection in patients with laryngeal SCC with high survivin expression.
OBJECTIVES: Functioning simultaneously at cell division and apoptosis inhibition, survivin, a member of the inhibitor of apoptosis proteins family, plays a pivotal role in determining cell survival. Significant over-expression of survivin has been demonstrated in most human malignancies and correlated with more aggressive forms. This review focuses on the attempts to translate survivin biologic properties toward both a diagnostic/prognostic tool and a novel therapeutic target in head and neck SCC (HNSCC).
MATERIALS AND METHODS: An exhaustive review of literature was performed to investigate available evidence about survivin expression, biological role and therapeutic potential in HNSCC.
RESULTS: Multiple evidence indicates that, in HNSCC cell lines, survivin inhibition by gene therapy and by small molecule inhibitors significantly increases the anti-tumour activity of several cytotoxic and other targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19322702     DOI: 10.3109/00016480902856588

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  6 in total

1.  Rationale behind survivin inhibition as a potential therapeutic strategy in head and neck carcinoma too.

Authors:  Gino Marioni
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

2.  Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.

Authors:  Neil E Bhola; Maria L Freilino; Sonali C Joyce; Malabika Sen; Sufi M Thomas; Anirban Sahu; Andre Cassell; Ching-Shih Chen; Jennifer R Grandis
Journal:  Mol Cancer Ther       Date:  2012-04-05       Impact factor: 6.261

3.  Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck.

Authors:  Yoon Ho Ko; Sang-Young Roh; Hye Sung Won; Eun Kyoung Jeon; Sook Hee Hong; Myung Ah Lee; Jin Hyoung Kang; Young Seon Hong; Min Sik Kim; Chan-Kwon Jung
Journal:  Head Neck Oncol       Date:  2010-10-30

4.  An indirubin derivative, indirubin-3'-monoxime suppresses oral cancer tumorigenesis through the downregulation of survivin.

Authors:  Wan-Yu Lo; Nai-Wen Chang
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

5.  Proteomic analysis of hypopharyngeal and laryngeal squamous cell carcinoma sheds light on differences in survival.

Authors:  Jiajia Liu; Weiming Zhu; Zhexuan Li; Gengming Cai; Juncheng Wang; Qinglai Tang; Christopher A Maroun; Gangcai Zhu
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

Review 6.  Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer.

Authors:  Tasia Bos; J Alex Ratti; Hisashi Harada
Journal:  Front Oral Health       Date:  2021-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.